MAGE-C2 Antibodies

Target Information

Proposed to enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. In vitro enhances ubiquitin ligase activity of TRIM28 and stimulates p53/TP53 ubiquitination in presence of Ubl-conjugating enzyme UBE2H leading to p53/TP53 degradation. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzymes (E2) at the E3:substrate complex. Not expressed in normal tissues, except in germ cells in the seminiferous tubules and in Purkinje cells of the cerebellum. Expressed in various tumors, including melanoma, lymphoma, as well as pancreatic cancer, mammary gland cancer, non-small cell lung cancer and liver cancer. In hepatocellular carcinoma, there is an inverse correlation between tumor differentiation and protein expression, i.e. the lower the differentiation, the higher percentage of expression. Note: This description may include information from UniProtKB.

Alternate Names

Cancer/testis antigen 10; CT10; HCA587; hepatocellular cancer antigen 587; Hepatocellular carcinoma-associated antigen 587; MAGC2; MAGE family member C2; MAGE-C2; MAGE-C2 antigen; MAGE-E1 antigen; MAGEC2; MAGEE1; melanoma antigen family C, 2; melanoma antigen family C2; melanoma antigen, family E, 1, cancer/testis specific; Melanoma-associated antigen C2; MGC13377